Silver Book Fact

Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.

Kurlan, R., Clark S., Shoulson Ira, et al. Economic Impact of Protective Therapy for Early Parkinsonâ??s Disease. Ann Neurol. 1988; 24(1): 153

Reference

Title
Economic Impact of Protective Therapy for Early Parkinsonâ??s Disease
Publication
Ann Neurol
Publication Date
1988
Authors
Kurlan, R., Clark S., Shoulson Ira, et al.
Volume & Issue
Volume 24, Issue 1
Pages
153

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 out-of-pocket costs to individuals and families dealing with the…  
  • “If you or a loved one started exhibiting symptoms of Alzheimer’s disease 12 years ago, there were no medicines for you to take. All you could do was hope–that…  
  • A current drug in development addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization.  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.